Zahra Tahmasebi Fard - Assistant Professor of Molecular Biology, Islamic Azad University, Roudehen Branch,Roudehen, IRAN.
Nahid Nafisi - Breast Cancer Surgery Fellowship, Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IRAN
Afsoon Taghavi - PhD of Genetics, Cancer Research Center, Shahid Beheshti University of Medical Sciences,Tehran, IRAN.

Background and Aim:The Fas protein is a member of the TNF-receptor superfamily. Interaction of FAS with Fas ligand is critical in triggering apoptosis of some types of cells such as lymphocytes. Alteration of the FAS/FAS ligand (FASLG) pathway regulating cell death may lead to cancer development such as breast cancer. Methods:We studied 100 patients and 100 healthy population that their sexes and ages matched case subjects with no history of cancer. DNA genomic was extracted from peripheral blood with standard protocol. We genotyped the single-nucleotide polymorphisms of FAS -1377 G > A and Fas Ligand 844 C˃T, by the PCR-RFLP assay. Results: The Hardy-Weinberg equilibrium analysis was performed by comparing the observed and expected genotypes frequencies in controls using the χ2 test. The results showed that the genotypes AA 52%, GG 41%, AG / GA 7% of Fas 1377 G / A in breast cancer cases and genotypes AA 34%, GG 47%, AG / GA19% among control group. Statistically, significant correlation was observed between the two groups. (P-Value ˃0.01) Conclusion:Our study showed that functional FAS -1377 G/A and FASL -844 T/C polymorphisms are associated with the risk of breast cancer of Iranian patients, but FASL -844 T/C polymorphisms showed a weak correlation

Fas 1377, Fas ligand 844, polymorphisms, RFLP-PCR, Breast cancer